This page follows insider dealings at 漢田生技 as filed with TWSE / TPEx (MOPS), a company from the Food & Beverage sector. 2 insiders have disclosed 3 filings since 22 October 2025.
Not one of the filings records a straightforward purchase or sale on the market. Compensation-driven entries like these are tracked, but they say little about how insiders judge the share price.
There has been no open-market purchase by an insider of 漢田生技 for at least a year. Most trades are made public on the day they happen. This delay matters because a trade only becomes useful information once it is public.
Across the 620 companies tracked on its exchange, the median is 2 filings; at 3 filings, this issuer sits above that mark.
This summary is built from TWSE / TPEx (MOPS) disclosures alone and does not predict where the share price will go.
Transparent value + quality ranking, distinct from the insider signal.
FY ended December 2025 · cache
7 of 7 declarations
漢田生技 is a company listed on the XTAI market, specializing in the biotechnology sector. It focuses on developing innovative solutions in the healthcare field.